|
1
|
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.
|
N Engl J Med
|
2008
|
12.90
|
|
2
|
Oral fingolimod (FTY720) for relapsing multiple sclerosis.
|
N Engl J Med
|
2006
|
7.18
|
|
3
|
Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial.
|
Ann Neurol
|
2009
|
3.35
|
|
4
|
Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial.
|
Arch Neurol
|
2007
|
1.86
|
|
5
|
Microglial expression of the B7 family member B7 homolog 1 confers strong immune inhibition: implications for immune responses and autoimmunity in the CNS.
|
J Neurosci
|
2005
|
1.43
|
|
6
|
Extensive cortical remyelination in patients with chronic multiple sclerosis.
|
Brain Pathol
|
2007
|
1.41
|
|
7
|
Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation.
|
Ann Neurol
|
2013
|
1.27
|
|
8
|
Pathogenesis of multiple sclerosis.
|
Curr Opin Neurol
|
2005
|
1.16
|
|
9
|
Suppression of Rac activity induces apoptosis of human glioma cells but not normal human astrocytes.
|
Cancer Res
|
2002
|
1.10
|
|
10
|
Expression of the immune-tolerogenic major histocompatibility molecule HLA-G in multiple sclerosis: implications for CNS immunity.
|
Brain
|
2005
|
0.98
|
|
11
|
Reconstitution of circulating lymphocyte counts in FTY720-treated MS patients.
|
Clin Immunol
|
2010
|
0.92
|
|
12
|
Oligodendrocyte injury in multiple sclerosis: a role for p53.
|
J Neurochem
|
2003
|
0.92
|
|
13
|
Response of human oligodendrocyte progenitors to growth factors and axon signals.
|
J Neuropathol Exp Neurol
|
2010
|
0.90
|
|
14
|
Contrasting potential of nitric oxide and peroxynitrite to mediate oligodendrocyte injury in multiple sclerosis.
|
Glia
|
2007
|
0.89
|
|
15
|
Oligodendrocyte progenitor cell susceptibility to injury in multiple sclerosis.
|
Am J Pathol
|
2013
|
0.88
|
|
16
|
Blood-brain barrier promotes differentiation of human fetal neural precursor cells.
|
Stem Cells
|
2009
|
0.87
|
|
17
|
Reduced thymic output and peripheral naïve CD4 T-cell alterations in primary progressive multiple sclerosis (PPMS).
|
J Neuroimmunol
|
2011
|
0.87
|
|
18
|
Thymic involution and proliferative T-cell responses in multiple sclerosis.
|
J Neuroimmunol
|
2010
|
0.86
|
|
19
|
Naive CD4 T-cell activation identifies MS patients having rapid transition to progressive MS.
|
Neurology
|
2014
|
0.82
|
|
20
|
Human fetal oligodendrocyte progenitor cells from different gestational stages exhibit substantially different potential to myelinate.
|
Stem Cells Dev
|
2012
|
0.82
|
|
21
|
The PTEN inhibitor bisperoxovanadium enhances myelination by amplifying IGF-1 signaling in rat and human oligodendrocyte progenitors.
|
Glia
|
2013
|
0.81
|
|
22
|
Limited TCF7L2 expression in MS lesions.
|
PLoS One
|
2013
|
0.80
|
|
23
|
Basis for fluctuations in lymphocyte counts in fingolimod-treated patients with multiple sclerosis.
|
Neurology
|
2013
|
0.79
|
|
24
|
Non-steroidal anti-inflammatory drug indometacin enhances endogenous remyelination.
|
Acta Neuropathol
|
2015
|
0.79
|
|
25
|
Cross-reactivity between epidemiology and immunology in multiple sclerosis.
|
Neurology
|
2008
|
0.75
|
|
26
|
Chronic cerebrospinal venous insufficiency.
|
Mult Scler
|
2010
|
0.75
|
|
27
|
Erratum: USP15 regulates type I interferon response and is required for pathogenesis of neuroinflammation.
|
Nat Immunol
|
2016
|
0.75
|
|
28
|
Editor's commentary.
|
Mult Scler
|
2015
|
0.75
|
|
29
|
Message from the Editors.
|
Mult Scler
|
2012
|
0.75
|
|
30
|
Therapeutic trial outcome studies.
|
Mult Scler
|
2012
|
0.75
|
|
31
|
Message from the editors.
|
Mult Scler
|
2013
|
0.75
|